COVID-19与血栓形成及抗凝治疗的相关性
简述:COVID-19感染可伴随凝血病,表现类似DIC的感染诱导炎症改变。肺部为靶器官,可进展为呼吸衰竭。初诊常见D-二聚体和纤维蛋白降解产物显著升高,而PT、aPTT和血小板异常相对少见。建议筛查凝血指标,按危重患者常规进行血栓预防,不推荐全剂量抗凝除非有临床指征。
要点
- COVID-19相关凝血病初诊以D-二聚体和纤维蛋白降解产物升高为主。
- 建议筛查D-二聚体和纤维蛋白原等凝血指标。
- 按危重患者常规血栓预防,不推荐全剂量抗凝除非有指征。
核心结论
- COVID-19相关凝血病应按危重患者常规管理,采用血栓预防和标准支持治疗。
- 当前数据不支持使用全强度抗凝剂量,除非有其他临床指征。
主要发现
- COVID-19初诊凝血病表现为D-二聚体和纤维蛋白/纤维蛋白原降解产物显著升高。
- 凝血酶原时间、部分凝血活酶时间和血小板计数异常在初诊时相对少见。
- 即使合并DIC,也未报告出血表现。
关键数值与推荐
- 建议筛查凝血指标,包括D-二聚体和纤维蛋白原水平。
- 对危重住院患者采用血栓栓塞预防。
- 脓毒症诱导凝血病或DIC患者采用标准支持治疗。
- D-二聚体、脓毒症生理和消耗性凝血病是死亡率指标。
临床怎么用
- 对COVID-19患者筛查D-二聚体和纤维蛋白原等凝血指标。
- 按危重患者常规进行血栓预防,不常规使用全剂量抗凝。
- 出现出血时按标准DIC和出血管理指南处理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Severe acute respiratory syndrome coronavirus 2, coronavirus disease 2019 (COVID-19)-induced infection can be associated with a coagulopathy, findings consistent with infection-induced inflammatory changes as observed in patients with disseminated intravascular coagulopathy (DIC). The lack of prior immunity to COVID-19 has resulted in large numbers of infected patients across the globe and uncertainty regarding management of the complications that arise in the course of this viral illness. The lungs are the target organ for COVID-19; patients develop acute lung injury that can progress to respiratory failure, although multiorgan failure can also occur. The initial coagulopathy of COVID-19 presents with prominent elevation of D-dimer and fibrin/fibrinogen-degradation products, whereas abnormalities in prothrombin time, partial thromboplastin time, and platelet counts are relatively uncommon in initial presentations. Coagulation test screening, including the measurement of D-dimer and fibrinogen levels, is suggested. COVID-19-associated coagulopathy should be managed as it would be for any critically ill patient, following the established practice of using thromboembolic prophylaxis for critically ill hospitalized patients, and standard supportive care measures for those with sepsis-induced coagulopathy or DIC. Although D-dimer, sepsis physiology, and consumptive coagulopathy are indicators of mortality, current data do not suggest the use of full-intensity anticoagulation doses unless otherwise clinically indicated. Even though there is an associated coagulopathy with COVID-19, bleeding manifestations, even in those with DIC, have not been reported. If bleeding does occur, standard guidelines for the management of DIC and bleeding should be followed.
引用
- Connors JM, Levy JH. COVID-19 and its implications for thrombosis and anticoagulation. Blood. 2020. PMID: 32339221. doi:10.1182/blood.2020006000
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。